PL1735348T3 - Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu - Google Patents

Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu

Info

Publication number
PL1735348T3
PL1735348T3 PL05732383T PL05732383T PL1735348T3 PL 1735348 T3 PL1735348 T3 PL 1735348T3 PL 05732383 T PL05732383 T PL 05732383T PL 05732383 T PL05732383 T PL 05732383T PL 1735348 T3 PL1735348 T3 PL 1735348T3
Authority
PL
Poland
Prior art keywords
growth factor
factor receptor
epidermal growth
human anti
receptor antibody
Prior art date
Application number
PL05732383T
Other languages
English (en)
Inventor
Meilin Liu
Zhenping Zhu
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of PL1735348T3 publication Critical patent/PL1735348T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
PL05732383T 2004-03-19 2005-03-21 Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu PL1735348T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55455504P 2004-03-19 2004-03-19
US62426404P 2004-11-02 2004-11-02
EP05732383A EP1735348B1 (en) 2004-03-19 2005-03-21 Human anti-epidermal growth factor receptor antibody
PCT/US2005/009583 WO2005090407A1 (en) 2004-03-19 2005-03-21 Human anti-epidermal growth factor receptor antibody

Publications (1)

Publication Number Publication Date
PL1735348T3 true PL1735348T3 (pl) 2012-11-30

Family

ID=34964896

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05732383T PL1735348T3 (pl) 2004-03-19 2005-03-21 Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu

Country Status (18)

Country Link
US (1) US7598350B2 (pl)
EP (2) EP1735348B1 (pl)
JP (1) JP4734319B2 (pl)
CN (1) CN103007279B (pl)
AU (1) AU2005224267B2 (pl)
CA (1) CA2560305C (pl)
CY (2) CY1113037T1 (pl)
DK (1) DK1735348T3 (pl)
ES (1) ES2387809T3 (pl)
HU (1) HUS000495I2 (pl)
LT (1) LTC1735348I2 (pl)
LU (1) LU93093I2 (pl)
MX (1) MXPA06010715A (pl)
NL (1) NL300819I2 (pl)
PL (1) PL1735348T3 (pl)
PT (1) PT1735348E (pl)
RU (1) RU2402569C2 (pl)
WO (1) WO2005090407A1 (pl)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
EE200100603A (et) * 1999-05-14 2003-02-17 Imclone Systems Incorporated Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega
CA2418083A1 (en) * 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
ES2466716T3 (es) * 2002-11-08 2014-06-11 Ablynx N.V. Anticuerpos de un solo dominio estabilizados
EP3299393A1 (en) * 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP2267032A3 (en) * 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
WO2007092453A2 (en) 2006-02-03 2007-08-16 Imclone Systems Incorporated Igf-ir antagonists as adjuvants for treatment of prostate cancer
CN101058609B (zh) * 2006-05-26 2011-04-13 神州细胞工程有限公司 人源抗体及其表达
WO2007147001A2 (en) * 2006-06-14 2007-12-21 Imclone Systems Incorporated Lyophilized formulations of anti-egfr antibodies
US20090280503A1 (en) * 2006-09-15 2009-11-12 James Fiore Method for detecting and treating skin disorders
US7820159B2 (en) * 2006-10-31 2010-10-26 Instiute of Virology of the Slovak Academy of Sciences MN/CA IX and EGFR pathway inhibition
WO2009067242A2 (en) * 2007-11-20 2009-05-28 Imclone Llc Co-crystal of antibody 11f8 fab fragment and egfr extracellular domain and uses thereof
MX2010007357A (es) * 2008-01-03 2011-03-03 The Scripps Res Institute Star Puesta de anti-cuerpos en objetivo mediante un dominio de reconocimiento modular.
WO2009105557A1 (en) * 2008-02-20 2009-08-27 Arizona Biomedical Research Commission Use of therapeutic peptides for the treatment and prevention of cancer
PT2325648E (pt) 2008-08-05 2014-06-24 Toray Industries Método para detetar cancro
CA2733223C (en) * 2008-08-05 2018-02-27 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers
JP5851842B2 (ja) 2009-01-12 2016-02-03 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. 改変した抗体組成物、それを作製および使用する方法
KR101108642B1 (ko) 2009-09-29 2012-02-09 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체
CN101704891B (zh) 2009-11-11 2011-11-09 中国人民解放军军事医学科学院生物工程研究所 一种针对表皮生长因子受体的抗体及其编码基因与应用
CN101875696B (zh) 2009-11-11 2012-02-08 中国人民解放军军事医学科学院生物工程研究所 一种抗体及其制备方法与应用
CN101875695B (zh) * 2009-11-11 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 一种抗体及其编码基因与应用
EP2933269A1 (en) 2009-12-18 2015-10-21 Sanofi Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
EP2532364B1 (en) 2010-02-04 2016-05-04 Toray Industries, Inc. Pharmaceutical composition comprising anti caprin-1 antibodies for treating and/or preventing cancer
EP2532367B1 (en) 2010-02-04 2018-08-29 Toray Industries, Inc. Pharmaceutical agent for treatment and/or prevention of cancer
HUE030103T2 (en) 2010-02-04 2017-04-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
JP5906739B2 (ja) 2010-02-04 2016-04-20 東レ株式会社 癌の治療及び／又は予防用医薬組成物
BR112012018951C8 (pt) 2010-02-04 2020-06-23 Toray Industries anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
WO2012018260A1 (en) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Epidermal growth factor receptor targeted immune therapy
WO2012033953A1 (en) 2010-09-08 2012-03-15 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
KR101273918B1 (ko) 2010-09-17 2013-06-13 강원대학교산학협력단 인간 항-상피세포성 성장인자수용체 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물
WO2012051247A2 (en) 2010-10-12 2012-04-19 Arizona Biomedical Research Commission Egfr-based peptides
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
AU2011320314B2 (en) 2010-10-29 2015-08-06 Immunogen, Inc. Novel EGFR-binding molecules and immunoconjugates thereof
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
WO2012143499A2 (de) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
PT3351630T (pt) 2011-08-04 2019-12-30 Toray Industries Composição farmacêutica compreendendo anticorpos anti caprin-1 para tratar e/ou prevenir o cancro
CA2844037C (en) 2011-08-04 2020-07-14 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
MX348578B (es) 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
CA2844038C (en) 2011-08-04 2019-05-07 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
HUE033183T2 (en) 2011-08-04 2017-11-28 Toray Industries A medicament for treating and / or preventing cancer
KR101984554B1 (ko) 2011-08-04 2019-05-31 도레이 카부시키가이샤 췌장암의 검출 방법
CN103764825B (zh) 2011-08-04 2015-09-02 东丽株式会社 癌的治疗和/或预防用药物组合物
KR20140105765A (ko) 2011-11-21 2014-09-02 이뮤노젠 아이엔씨 EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법
ES2749672T3 (es) 2012-02-21 2020-03-23 Toray Industries Composición farmacéutica para tratar y/o prevenir el cáncer
KR102009238B1 (ko) 2012-02-21 2019-08-09 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
WO2013125640A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び／又は予防用医薬組成物
IN2014KN01715A (pl) 2012-02-21 2015-10-23 Toray Industries
SG11201405553YA (en) 2012-03-08 2014-11-27 Halozyme Inc Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
EP2832366B1 (en) 2012-03-30 2017-11-08 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
EP2832365B1 (en) 2012-03-30 2017-11-01 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
JP6441792B2 (ja) * 2012-05-17 2018-12-19 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｅｇｆｒに結合する抗原結合蛋白質
JP6103832B2 (ja) 2012-06-25 2017-03-29 Hoya株式会社 Ｅｇｆｒ結合性ペプチド
PT2876447T (pt) 2012-07-19 2020-02-03 Toray Industries Método para deteção de cancro
TR201902972T4 (tr) 2012-07-19 2019-03-21 Toray Industries Kanseri tespit etmek için yöntem.
US9862932B2 (en) 2012-07-24 2018-01-09 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
US9921222B2 (en) 2012-07-31 2018-03-20 Crown Bioscience, Inc. (Taicang) Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-EGFR drug
US9605074B2 (en) * 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
CN102993305B (zh) * 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 人源抗人表皮生长因子受体抗体及其编码基因与应用
RU2652880C2 (ru) * 2013-04-07 2018-05-03 Дженрикс (Шанхай) Байофармасертикал Ко., Лтд. Антитело против рецептора эпидермального фактора роста
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2015020212A1 (ja) 2013-08-09 2015-02-12 東レ株式会社 癌の治療及び／又は予防用医薬組成物
EP3044236A2 (en) 2013-09-12 2016-07-20 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
PT3083694T (pt) * 2013-12-20 2024-02-01 Intervet Int Bv Anticorpos murinos caninizados anti-pd-1 canino
CN106163568B (zh) 2013-12-23 2021-03-23 拜耳制药股份公司 含纺锤体驱动蛋白（ksp）的抗体药物偶联物（adc）
JP6447887B2 (ja) 2014-03-03 2019-01-09 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 二重特異性抗体及びその使用
AU2015292590B2 (en) * 2014-07-24 2020-01-16 2Seventy Bio, Inc. BCMA chimeric antigen receptors
CN108251431B (zh) 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
WO2016161440A2 (en) 2015-04-03 2016-10-06 Arizona Cancer Therapeutics, Llc Egfr-based inhibitor peptides for combinatorial inactivation of erbb1, erbb2, and erbb3
TW201703769A (zh) 2015-05-08 2017-02-01 美國禮來大藥廠 用於癌症的組合療法
PE20180610A1 (es) 2015-06-22 2018-04-09 Bayer Pharma AG CONJUGADOS DE LIGADOR-PRINCIPIO ACTIVO (ADCs) Y CONJUGADOS DE LIGADOR-PROFARMACO (APDCs) CON GRUPOS ENZIMATICAMENTE ESCINDIBLES
PE20180452A1 (es) 2015-06-23 2018-03-05 Bayer Pharma AG Conjugados homogeneos especificos de sitio con inhibidores de ksp
TW201716439A (zh) 2015-07-20 2017-05-16 美國禮來大藥廠 Ｈｅｒ３抗體
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
WO2017160568A1 (en) 2016-03-16 2017-09-21 Eli Lilly And Company Combination therapy comprising the cdk4/6 inhibitor necitumumab and the egfr inhibitor abemaciclib for use in treating cancer
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
US11685714B2 (en) 2016-03-24 2023-06-27 Bayer Pharma Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
CA3027445A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
EP3515940A1 (en) * 2016-09-26 2019-07-31 ImClone LLC Combination therapy for cancer
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
WO2018114798A1 (de) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
JP7072792B2 (ja) * 2017-12-11 2022-05-23 国立大学法人神戸大学 二重特異性抗体
KR20210116437A (ko) 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
CN113260379B (zh) * 2018-12-21 2022-09-02 浙江时迈药业有限公司 蛋白酶可切割的双特异性抗体及其用途
CA3154522A1 (en) 2019-10-15 2021-04-22 Christopher Carl Frye Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CN113527482B (zh) * 2020-04-17 2023-07-21 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
WO2022031783A2 (en) * 2020-08-05 2022-02-10 Ohio State Innovation Foundation Adapter polypeptides and methods of using the same
EP4223779A1 (en) * 2020-09-30 2023-08-09 Institute Of Zoology, Chinese Academy Of Sciences Egfr-targeting chimeric antigen receptor
WO2022140670A2 (en) * 2020-12-23 2022-06-30 Phenomic Ai Anti-activin antibodies and methods of using the same

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4186567A (en) 1977-04-18 1980-02-05 Hitachi Metals, Ltd. Ornament utilizing rare earth-cobalt magnet
US4510924A (en) 1980-07-10 1985-04-16 Yale-New Haven Hospital, Inc. Brachytherapy devices and methods employing americium-241
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5866363A (en) 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
US4816401A (en) 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
CA1275922C (en) 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
US4846782A (en) 1986-03-14 1989-07-11 Schering Corporation Treatment of cancer with interferon and radiotherapy
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4763642A (en) 1986-04-07 1988-08-16 Horowitz Bruce S Intracavitational brachytherapy
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0318554B2 (en) 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5470571A (en) 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
EP0362371A4 (en) 1988-04-15 1990-10-24 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
AU627183B2 (en) 1988-04-16 1992-08-20 Celltech Limited Method for producing recombinant dna proteins
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE179862T1 (de) 1989-07-06 1999-05-15 Univ California Rezeptoren für fibroblasten-wachstumsfaktoren
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0525109A4 (en) 1990-04-16 1993-06-30 Rhone-Poulenc Rorer International (Holdings) Inc. Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase
US5196446A (en) 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0531472T3 (da) 1991-03-06 2003-12-01 Merck Patent Gmbh Humaniserede monoklonale antistoffer
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US5550114A (en) 1993-04-02 1996-08-27 Thomas Jefferson University Epidermal growth factor inhibitor
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5840301A (en) 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
CZ288955B6 (cs) 1994-02-23 2001-10-17 Pfizer Inc. Substituované chinazolinové deriváty, jejich pouľití a farmaceutické prostředky na jejich bázi
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US5656655A (en) 1994-03-17 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase
ES2191702T3 (es) 1994-03-17 2003-09-16 Merck Patent Gmbh Fv monocatenarios anti-egfr y anticuerpos anti-egfr.
JP3249007B2 (ja) 1994-03-17 2002-01-21 富士通株式会社 半導体装置、その特性評価方法及び設計方法
US5869465A (en) 1994-04-08 1999-02-09 Receptagen Corporation Methods of receptor modulation and uses therefor
US5468754A (en) 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
US5604233A (en) 1994-04-28 1997-02-18 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5663144A (en) 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
EP0888349B1 (en) 1996-01-23 2002-05-22 Novartis AG Pyrrolopyrimidines and processes for their preparation
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
AU3305197A (en) 1996-06-06 1998-01-05 University Of Massachusetts Non-activated receptor complex proteins and uses thereof
BR9709959A (pt) 1996-06-24 2000-05-09 Pfizer Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
US6004967A (en) 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
DE69839338T2 (de) 1997-02-05 2008-07-10 Warner-Lambert Company Llc Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
US5942602A (en) 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US20030105057A1 (en) 1997-03-19 2003-06-05 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
US5914269A (en) 1997-04-04 1999-06-22 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of epidermal growth factor receptor expression
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20020173629A1 (en) * 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
IL139707A0 (en) * 1998-05-15 2002-02-10 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
IL142121A0 (en) 1998-09-29 2002-03-10 American Cyanamid Co Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
DE69904358T2 (de) 1998-11-19 2003-04-17 Warner Lambert Co N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morfolin-4-yl-propoxy)-chinazolin-6-yl -akrylamid, ein irreversibler tyrosin-kinasen hemmer
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
EE200100603A (et) * 1999-05-14 2003-02-17 Imclone Systems Incorporated Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega
ES2321568T3 (es) 1999-05-18 2009-06-08 Dyax Corp. Bibliotecas de fragmentos fab y procedimientos para su uso.
EP2111870A1 (en) * 1999-08-27 2009-10-28 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies
CA2418083A1 (en) * 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
CA2422881A1 (en) 2000-10-13 2002-04-18 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
AU2002239486A1 (en) 2000-12-08 2002-06-18 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
US20040116330A1 (en) 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
AU2002345673B2 (en) * 2001-06-13 2007-04-26 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
DE10163459A1 (de) 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
JP2005518789A (ja) * 2002-01-28 2005-06-30 メダレックス， インク． 前立腺特異性膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体
DE60333554D1 (de) 2002-03-04 2010-09-09 Imclone Llc Kdr-spezifische humane antikörper und deren anwendung
ATE494000T1 (de) 2002-03-08 2011-01-15 Max Planck Gesellschaft Verwendung von egfr transaktivierungsinhibitoren für menschlichen krebs
WO2003079997A2 (en) * 2002-03-21 2003-10-02 Cayman Chemical Company Prostaglandin f2 alpha analogs in combinaiotn with antimicrobials for treating glaucoma
EP1510221A4 (en) 2002-06-03 2009-04-29 Mitsubishi Tanabe Pharma Corp MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERSONS EXPRESSING OR ACTIVATING HER2 AND / OR EGFR
WO2004005890A2 (en) * 2002-07-03 2004-01-15 The Trustees Of The University Of Pennsylvania Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof
RU2354402C2 (ru) * 2002-10-10 2009-05-10 Мерк Патент Гмбх ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, НАПРАВЛЕННЫЕ НА РЕЦЕПТОРЫ ErbB1
EP2365001A3 (en) 2003-05-01 2012-03-28 Imclone LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
DE60334645D1 (de) * 2003-11-07 2010-12-02 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
DE10355904A1 (de) * 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
RU2390353C2 (ru) * 2004-02-12 2010-05-27 Мерк Патент Гмбх Высококонцентрированные жидкие композиции анти-egfr антител
TW200533339A (en) * 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
JP5835204B2 (ja) 2012-12-20 2015-12-24 信越化学工業株式会社 レジスト材料及びこれを用いたパターン形成方法

Also Published As

Publication number Publication date
CY1113037T1 (el) 2016-04-13
PT1735348E (pt) 2012-07-24
WO2005090407A8 (en) 2005-12-01
AU2005224267B2 (en) 2011-07-21
DK1735348T3 (da) 2012-07-16
HUS1600030I1 (hu) 2016-07-28
RU2006137060A (ru) 2008-04-27
RU2402569C2 (ru) 2010-10-27
CN103007279B (zh) 2017-01-11
NL300819I2 (pl) 2016-07-21
HUS000495I2 (hu) 2021-03-29
CY2016016I2 (el) 2016-12-14
CN103007279A (zh) 2013-04-03
MXPA06010715A (es) 2007-05-23
EP1735348B1 (en) 2012-06-20
EP2332990A1 (en) 2011-06-15
LTC1735348I2 (lt) 2017-11-10
US7598350B2 (en) 2009-10-06
CA2560305A1 (en) 2005-09-29
CA2560305C (en) 2016-07-05
ES2387809T3 (es) 2012-10-02
US20070264253A1 (en) 2007-11-15
AU2005224267A1 (en) 2005-09-29
JP4734319B2 (ja) 2011-07-27
WO2005090407A1 (en) 2005-09-29
CY2016016I1 (el) 2016-12-14
EP1735348A1 (en) 2006-12-27
LU93093I2 (fr) 2016-08-01
JP2008500815A (ja) 2008-01-17

Similar Documents

Publication Publication Date Title
HUS1600030I1 (hu) Humán anti-epidermális növekedési faktor receptor ellenanyag
EP1810979A4 (en) STABILIZED HUMAN IgG4 ANTIBODIES
IL237756A0 (en) Antibody compositions
IL179672A0 (en) Anti-cd3 antibodies
IL173273A0 (en) Modified human igf-1r antibodies
IL181575A0 (en) Anti-ox40l antibodies
EP1765868A4 (en) ANTIBODY AGAINST THE TRANSFERRIN RECEPTOR
IL228032A0 (en) Antibodies
ZA200507067B (en) Antibodies against human IL-21 receptor and uses therefor
HK1153209A1 (en) Antagonistic human light-specific human monoclonal antibodies
ZA200608100B (en) IRTA-5 antibodies and their uses
IL180789A0 (en) Human monoclonal antibodies against human il-4
GB0420466D0 (en) Anti-glucan antibodies
SI1735348T1 (sl) Äśloveĺ ko anti-egfr protitelo
ZA200704926B (en) Modified human growth hormone
IL172511A0 (en) Specific human antibodies
ZA200701952B (en) Anti-OX40L antibodies
EP1812794A4 (en) AUTOKRINE GROWTH FACTOR RECEPTORS AND METHOD
EP1780221A4 (en) ANTI-SYNOVIOLIN ANTIBODY
PL383490A1 (pl) Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu
ZA200702281B (en) IRTA-4 antibodies and their uses
GB0418415D0 (en) Antibody
GB0502201D0 (en) Human antibodies
SI1656391T1 (sl) Modificirana humana IGF-1R protitelesa
GB0402641D0 (en) Antibodies